Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Taltz ® (ixekizumab) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
COAST-X (N=303) is a phase 3, 52-week double-blind, placebo-controlled trial in patients with nr-axSpA who are naive to bDMARDs.1
Reported reasons for discontinuation of study drug in patients that remained in their original treatment arm is shown in Table 1.
Table 1. Reasons for Discontinuation of Study Drug Through Week 52 of COAST-X, Prior to any Switch to Open-Label Ixekizumab Every 2 Weeks1
Reason for discontinuation, n |
PBO |
IXE
Q4W |
IXE
Q2W |
Withdrawal by participant |
7 |
2 |
6 |
Adverse event |
2a |
1b |
1c |
Lack of efficacy |
0 |
1 |
0 |
Lost to follow-up |
0 |
0 |
1 |
Abbreviations: AE = adverse event; ALT = alanine aminotransferase; IXE Q2W = ixekizumab 80 mg every 2 weeks; IXE Q4W = ixekizumab 80 mg every 4 weeks; PBO = placebo.
a AEs were ALT increased and anaphylactoid reaction.
b AE was psoriasis.
c AE was syncope.
The dosing schedule IXE Q2W is not consistent with the approved dosing schedule for axial spondyloarthritis in the Taltz Summary of Product Characteristics. Please refer to the Taltz Summary of Product Characteristics for approved dosing.2
Starting at week 16 of the COAST-X trial, patients whose disease activity required escalation of treatment could be switched to open-label ixekizumab 80 mg Q2W or subsequent anti-TNF therapy (after a minimum of 8 weeks of open-label ixekizumab treatment) at the discretion of the treating rheumatologist without further specification. The proportions of patients in each treatment arm who switched to open-label ixekizumab 80 mg Q2W were
62/105 (59%) in the placebo arm
40/96 (42%) for the ixekizumab Q4W arm, and
42/102 (41%) for the ixekizumab Q2W arm.1
Reported reasons for discontinuation of patients who switched to open-label ixekizumab 80 mg Q2W after week 16 are shown in Table 2. Of 144 total patients who switched to open-label ixekizumab treatment, 127 patients (88.2%) remained on open-label ixekizumab treatment through week 52.1
Table 2. Reasons for Discontinuation of Study Drug Through Week 52 of COAST-X, After Switch to Open-Label Ixekizumab Every 2 Weeks1
Reason for Discontinuation, n |
PBO
to IXE Q2W |
IXE
Q4W to IXE Q2W |
IXE
Q2W to IXE Q2W |
Withdrawal by participant |
2 |
1 |
1 |
Adverse Event |
3a |
0 |
1b |
Lack of efficacy |
2 |
1 |
4 |
Withdrawal by physician |
0 |
0 |
1 |
Other |
0 |
1 |
0 |
Abbreviations: AE = adverse event; IXE Q2W = ixekizumab 80 mg every 2 weeks; IXE Q4W = ixekizumab 80 mg every 4 weeks; PBO = placebo.
a AEs were C. difficile infection, injection site erythema, and injection site reaction.
1. Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53-64. http://dx.doi.org/10.1016/S0140-6736(19)32971-X
2. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Glossary
bDMARD = biologic disease-modifying antirheumatic drug
nr-axSpA = nonradiographic axial spondyloarthritis
Q2W = every 2 weeks
Q4W = every 4 weeks
TNF = tumor necrosis factor
Datum fӧr senaste ӧversyn 2020 M04 16